摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-溴-5-甲氧基苯胺盐酸盐 | 129968-11-2

中文名称
2-溴-5-甲氧基苯胺盐酸盐
中文别名
——
英文名称
3-amino-4-bromoanisole hydrochloride
英文别名
2-bromo-5-methoxyaniline hydrochloride;2-Brom-5-methoxy-anilin; Hydrochlorid;2-bromo-5-methoxyaniline;hydrochloride
2-溴-5-甲氧基苯胺盐酸盐化学式
CAS
129968-11-2
化学式
C7H8BrNO*ClH
mdl
——
分子量
238.512
InChiKey
UTLMWQABYASJPQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    186 °C

计算性质

  • 辛醇/水分配系数(LogP):
    2.46
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    35.2
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2922299090
  • 危险性防范说明:
    P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:03a74266b8c895e6b627a1bdb5b08d70
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Bromo-5-methoxyaniline, HCl
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-5-methoxyaniline, HCl
CAS number: 129968-11-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H9BrClNO
Molecular weight: 238.5

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Carboxyl-mediated Pictet-Spengler reaction. Direct synthesis of 1,2,3,4-tetrahydro-.beta.-carbolines from tryptamine-2-carboxylic acids
    摘要:
    The Pictet-Spengler condensation of various tryptamine-2-carboxylic acids 9a-f with carbonyl compounds in benzene/dioxane/trifluoroacetic acid (Table I) with simultaneous loss of carbon dioxide afforded directly the corresponding 1,2,3,4-tetrahydro-beta-carbolines 14a-j in good to excellent yields. This reaction greatly enhances the use of the Abramovitch-Shapiro method for the synthesis of highly oxygenated ring A substituted 1,2,3,4-tetrahydro-beta-carbolines (THBC). The lactams 14f,g and 14h are key intermediates for the synthesis of ring A substituted 1-methoxycanthin-6-one analogues.
    DOI:
    10.1021/jo00001a066
  • 作为产物:
    描述:
    4-溴-3-硝基苯甲醚 在 iron(III) acetylacetonate 、 1,1,3,3-四甲基二硅氧烷盐酸 作用下, 以 四氢呋喃乙醚 为溶剂, 反应 24.08h, 以27%的产率得到2-溴-5-甲氧基苯胺盐酸盐
    参考文献:
    名称:
    使用TMDS-铁催化剂体系将芳族硝基还原为胺的替代方法
    摘要:
    本文报道了系统1,1,3,3-四甲基二硅氧烷(TMDS)/ Fe(acac)3作为从芳族硝基化合物获得胺的新方法。胺可通过简单的步骤进行合成,并以良好或极好的收率分离为盐酸盐形式。该系统显示出对芳基氯化物,芳基溴化物,酯,羧酸和氰基的良好选择性。 不幸的是,使用该方法无法还原烷基硝基化合物,仅获得了单和二烷基化胺的混合物。
    DOI:
    10.1016/j.tet.2010.12.070
点击查看最新优质反应信息

文献信息

  • [EN] QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES<br/>[FR] DERIVES DE QUINAZOLINE DESTINES AU TRAITEMENT DES MALADIES INDUITES PAR LES LYMPHOCYTES T
    申请人:ASTRAZENECA AB
    公开号:WO2003045395A1
    公开(公告)日:2003-06-05
    The invention concerns the use of the quinazoline derivatives of Formula (I) wherein each of Q1, Z, m, R1, R2, R3 and Q2 have any of the meanings defined in the description in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.
    本发明涉及使用式(I)中各自具有定义于本说明书中的任何含义的Q1、Z、m、R1、R2、R3和Q2的喹唑啉衍生物制造用于预防或治疗温血动物的T细胞介导疾病或医疗情况的药物。
  • [EN] QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS<br/>[FR] DERIVES DE LA QUINAZOLINE POUR LE TRAITEMENT DE TUMEURS
    申请人:ASTRAZENECA AB
    公开号:WO2001094341A1
    公开(公告)日:2001-12-13
    The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, m, R?1, R2, R3 and Q2¿ have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.
    本发明涉及公式(I)的喹唑啉衍生物,其中Q1,Z,m,R?1,R2,R3和Q2¿中的每一个都具有描述中定义的任何含义;制备它们的过程,含有它们的制药组合物以及它们在制造用于抗侵袭剂的药物,用于包含和/或治疗实体肿瘤疾病。
  • Quinazoline derivatives for treatment of tumours
    申请人:——
    公开号:US20040214841A1
    公开(公告)日:2004-10-28
    The invention concerns quinazoline derivatives of Formula (I) wherein each of Q 1 , Z, m, R 1 , R 2 , R 3 and Q 2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease. 1
    本发明涉及公式(I)的喹嗪衍生物,其中Q1、Z、m、R1、R2、R3和Q2中的每个都具有描述中定义的任何含义;制备它们的过程,包含它们的制药组合物以及它们在制造用于抗侵袭剂以限制和/或治疗实体肿瘤疾病的药物中的使用。
  • Quinazoline derivatives for the treatment of t cell mediated diseases
    申请人:Moore Corine Nelly
    公开号:US20050038050A1
    公开(公告)日:2005-02-17
    The invention concerns the use of the quinazoline derivatives of Formula (I) wherein each of Q 1 , Z, m, R 1 , R 2 , R 3 and Q 2 have any of the meanings defined in the description in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.
    本发明涉及在温血动物中预防或治疗T细胞介导的疾病或医疗状况的药物制剂的制造中使用公式(I)的喹唑啉衍生物,其中Q1,Z,m,R1,R2,R3和Q2中的每一个都具有描述中定义的任何含义。
  • Quinazoline derivatives for the treatment of tumours
    申请人:Hennequin Francois Andre Laurent
    公开号:US20060258642A1
    公开(公告)日:2006-11-16
    The invention concerns quinazoline derivatives of Formula (I) wherein each of Q 1 , Z, m, R 1 , R 2 , R 3 and Q 2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.
    本发明涉及公式(I)的喹唑啉衍生物,其中Q1,Z,m,R1,R2,R3和Q2中的每一个都具有描述中定义的任何含义;其制备过程,含有它们的制药组合物以及它们在制造用于抗侵袭剂在包含和/或治疗实体肿瘤疾病的药物中的应用。
查看更多